Eisai sees 62% profit gain this FY; Hikma founder Darwazah passes away;

> ASX and Nasdaq-listed Novogen ($NVGN) said it will present this week in Hong Kong on two drug technology platforms: the super-benzopyrans and the anti-tropomyocins. Release

> Taiwan's TWi Pharmaceutical has promoted its R&D executive vice president Jianbo Xie to chief operating officer on May 14. Release

> Eisai's operating profit is forecast to rise 62% to ¥46 billion ($386 million) in the year ending March 31, 2016. Story

> Researchers from Australia's University of Melbourne and Shanghai's Fudan University said they have discovered how flu-killing CD8+T-cells memorize strains of influenza and destroy them. Report

> Australia's Queensland Children's Medical Research Institute has released results from the world's first clinical trials of a new treatment that combined two existing drugs, lumacaftor and ivacaftor, for children suffering from cystic fibrosis that researchers said showed up to 39% fewer lung infections. Report

> Samih Darwazah, the founder and honorary life president of Middle East-based drug company Hikma Pharmaceuticals, passed away peacefully on Friday, 15 May, in London at the age of 85. Release

> U.S.-based SCIEX and the Protein and Protemics Centre of the Department of Biological Sciences of the National University of Singapore signed an MOU to promote joint research and development activities in oncology biomarker discovery and development. Release

> Japan's R-Tech Ueno announced a research tie-up with Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology at the Hokkaido University Graduate School of Medicine. Release